Impurity compound of sartan antihypertensive drug and preparation method thereof

By preparing bis[1,1’-[2-(1H-tetrazol-5-yl)phenyl]benzyl ether compound, the problem of difficult control of sartan-based impurities in the prior art was solved, and effective control of drug quality and improvement of purity were achieved.

CN120230054APending Publication Date: 2025-07-01HUIZHOU XINLITAI PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311868152.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-12-29
Publication Date
2025-07-01

AI Technical Summary

Technical Problem

The prior art is difficult to effectively control unknown impurities in sartan-based blood pressure-lowering drugs, affecting drug quality control.

Method used

A new impurity compound is prepared with a structure of bis[1,1'-[2-(1H-tetrazol-5-yl)phenyl]benzyl ether, and an intermediate is formed by reacting with an inorganic strong base in an organic solvent, and then removing the trityl protecting group under organic solvent and strong acid conditions to form the target compound.

Benefits of technology

New impurity compounds are provided as impurity controls for quality control of sartan drugs, improving drug purity and yield.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120230054A_ABST
    Figure CN120230054A_ABST
Patent Text Reader

Abstract

The invention discloses a compound shown in a formula (I) and a preparation method thereof. The compound is used as a reference substance of a novel potential process impurity in quality control of sartan antihypertensive drugs with biphenyl tetrazole structures, such as olmesartan medoxomil, allisartan medoxomil, losartan, candesartan cilexetil, ibesartan, valsartan and the like. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to chemical pharmaceuticals, and provides an impurity compound of a sartan antihypertensive drug and a preparation method thereof, especially the quality control of sartan antihypertensive drugs. Background Art

[0002] Antihypertensive oral drugs such as olmesartan medoxomil, allisartan isoproxil, losartan, candesartan cilexetil, irbesartan, valsartan, etc. are all selective angiotensin II receptor antagonists, and all have a biphenyltetrazole fragment in their molecular structures (the second part of the Chinese Pharmacopoeia 2020 edition).

[0003]

[0004] Among them, the tetrazole structure has a tautomeric phenomenon, and the hydrogen atom above can be either at the 1-position or the 2-position on the tetrazole ring. Both structural formulas represent the same compound. One of the representation methods is adopted in this article.

[0005]

[0006] When synthesizing the above sartan drugs, a tetrazole biphenyl benzyl bromide compound (BBTT) with a trityl protecting group can be considered as the starting material. BBTT undergoes a condensation reaction with the corresponding nitrogen-containing compound under alkaline conditions, and finally the trityl protecting group is removed to form the desired drug molecular structure (International Journal of PharmaResearch&Review, Nov 2014, 3(11):46 - 56).

[0007] A synthesis route of a sartan drug is as follows:

[0008]

[0009] When the inventors synthesized some sartan drugs such as olmesartan medoxomil, a trace amount of unknown impurity was found in the product. In order to better control the quality of the product, it is necessary to determine the structure of the unknown impurity and prepare relevant reference substances. Summary of the Invention

[0010] The present invention discloses new potential process impurities in sartan drugs with a biphenyltetrazole structure such as olmesartan medoxomil and a preparation method thereof.

[0011] The present invention provides a compound (bis[1,1'-[2-(1H-tetrazol-5-yl)phenyl]]benzyl ether) having the structure shown in the following formula (I):

[0012]

[0013] This compound is an impurity compound of a new sartan drug, and its use in preparing an impurity reference substance for sartan antihypertensive drugs having a biphenyltetrazole structure is provided.

[0014] The present invention further provides a preparation method of this substance, including the following steps:

[0015] (1) React N-trityltetrazole biphenylmethyl bromide (BBTT) with an inorganic strong base in an organic solvent to obtain a dimeric intermediate. As a preferred technical solution: the organic solvent includes dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone or tetrahydrofuran. The inorganic strong base includes sodium hydroxide, potassium hydroxide or lithium hydroxide.

[0016] (2) Remove the trityl protecting group from the product obtained in the previous step in an organic solvent under strong acid conditions to generate the target compound. As a preferred technical solution: the organic solvent includes methanol, ethanol, acetone, tetrahydrofuran, dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide and N-methylpyrrolidone. The strong acid used is sulfuric acid or hydrochloric acid.

[0017] The reaction formula is as follows:

[0018]

[0019] The beneficial effects of the present invention compared with the prior art include:

[0020] (1) The present invention provides an impurity compound of a new sartan drug, and its use in preparing an impurity reference substance for sartan antihypertensive drugs having a biphenyltetrazole structure is provided.

[0021] (2) The present invention further provides a preparation method of the impurity compound of the new sartan drug, and the preferred method has a better yield. Description of the Drawings

[0022] Figure 1 , 1H-NMR spectrum of Product I;

[0023] Figure 2 , HRMS(+) spectrum of Product I;

[0024] Figure 3 , HRMS(-) spectrum of Product I. Specific Examples

[0025] The present application will be further described in detail below in conjunction with embodiments and the accompanying drawings, but the embodiments of the present application are not limited thereto.

[0026] Example 1: Preparation of bis[1,1'-[2-(1H-tetrazol-5-yl)phenyl]]benzyl ether (I).

[0027] 70 g of BBTT was added to 300 ml of dimethyl sulfoxide, and 50 g of an aqueous sodium hydroxide solution with a concentration of 20% was added thereto under stirring. The temperature was raised to 40 °C and the reaction was carried out for 15 h until the reaction was substantially complete. 500 ml of water was added dropwise to precipitate solid (II). It was filtered, washed with water, and dried (yield 98%, purity 67%). The obtained intermediate solid was added to 350 ml of methanol, cooled to 5 - 10 °C, and 15 g of sulfuric acid was slowly added dropwise under stirring. The temperature was raised to 25 - 30 °C and the reaction was stirred for 12 h. The reaction solution was added dropwise to 1 L of water to precipitate a solid. The solid was collected and dried under vacuum.

[0028] It was treated by silica gel chromatography (the eluent was ethyl acetate / methanol = 20 / 1), the main peak fraction was collected, and after evaporation to dryness, about 18 g of pure product (I) was obtained, with a yield of 59% and a product purity of 93%.

[0029] It was detected by HPLC with reference to the conditions of olmesartan medoxomil in the 10.0th edition of the European Pharmacopoeia. The relative retention time of I was about 1.5 times that of olmesartan medoxomil.

[0030] As Figure 1 shown, H 1 -NMR (in d 6 -DMSO): δ4.54 (4H, s). δ7.07 (4H, d), δ7.28 (4H, dd); δ7.54 - 7.65 (4H, m); δ7.65 - 7.71 (4H, m).

[0031] As Figure 2 shown, HRMS (positive ion mode): C 28 H 22 N8O+H + The theoretical value of is 487.1995, and the measured value is 487.2367.

[0032] As Figure 3 shown, HRMS (negative ion mode): [C 28 H 22 N8O-H]- The theoretical value is 485.1838, and the measured value is 485.1315.

[0033] Comparative Example 1

[0034] Add 7 g of BBTT to 40 ml of acetone, add 1 g of granular sodium hydroxide, and stir and reflux for 24 h. HPLC detection shows that a large amount of raw materials did not participate in the reaction, and the peak of the hydrolysis intermediate (II) only accounts for about 5%.

[0035] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principle of the present invention shall be equivalent replacement methods and are all included in the protection scope of the present invention.

Claims

1. A compound having the structure shown in the following formula (I), characterized in that:

2. Use of the compound (I) as shown in claim 1 in the preparation of an impurity reference substance for a sartan antihypertensive drug having a biphenyltetrazole structure.

3. A method for preparing a compound represented by the following formula (I) as shown in claim 1, characterized in that, Comprising the following steps: (1) Reacting N-trityltetrazole biphenylmethyl bromide (BBTT) with an inorganic strong base in an organic solvent to obtain a dimeric intermediate; (2) Removing the trityl protecting group from the product obtained in the previous step in an organic solvent under strong acid conditions to form the target compound.

4. The method for preparing the compound (I) according to claim 3, characterized in that, The reaction formula is as follows:

5. The preparation method of the compound (I) according to claim 3 or 4, comprising the following steps: (1) Reacting N-trityltetrazole biphenylmethyl bromide (BBTT) with an inorganic strong base in an organic solvent to obtain a dimeric intermediate, wherein the organic solvent includes dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone or tetrahydrofuran. The inorganic strong base includes sodium hydroxide, potassium hydroxide or lithium hydroxide.

6. The method for preparing the compound (I) according to claim 5, characterized in that, The organic solvent in step (1) is dimethyl sulfoxide.

7. The preparation method of the compound (I) according to claim 3 or 4, comprising the following steps: (2) Removing the trityl protecting group from the product obtained in the previous step in an organic solvent under strong acid conditions to form the target compound; the organic solvent includes methanol, ethanol, acetone, tetrahydrofuran, dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide and N-methylpyrrolidone; the strong acid used is sulfuric acid or hydrochloric acid.

8. The method for preparing the compound (I) according to claim 7, characterized in that, The organic solvent in step (2) is methanol.

9. The method for preparing the compound (I) according to claim 7, characterized in that, The strong acid in step (2) is sulfuric acid.